A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma
- DOI
- 10.1007/s10637-021-01164-9
- Published
- 2021-08-21
- Container
- Investigational New Drugs
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s10637-021-01164-9,
title = {A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma},
author = {Hani Babiker and Peter J. Schlegel and Lee G. Hicks and Andrea J. Bullock and Nafisa Burhani and Daruka Mahadevan and Emad Elquza and Mitesh J. Borad and Ely Benaim and Christine Peterson and Callie Heaton and Allyson J. Ocean},
year = {2021},
journal = {Investigational New Drugs},
doi = {10.1007/s10637-021-01164-9},
url = {https://doi.org/10.1007/s10637-021-01164-9}
}RIS
TY - JOUR TI - A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma AU - Hani Babiker AU - Peter J. Schlegel AU - Lee G. Hicks AU - Andrea J. Bullock AU - Nafisa Burhani AU - Daruka Mahadevan AU - Emad Elquza AU - Mitesh J. Borad AU - Ely Benaim AU - Christine Peterson AU - Callie Heaton AU - Allyson J. Ocean PY - 2021 JO - Investigational New Drugs DO - 10.1007/s10637-021-01164-9 UR - https://doi.org/10.1007/s10637-021-01164-9 ER -
APA
Babiker, H., Schlegel, P. J., Hicks, L. G., Bullock, A. J., Burhani, N., Mahadevan, D., Elquza, E., Borad, M. J., Benaim, E., Peterson, C., Heaton, C., & Ocean, A. J. (2021). A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma. Investigational New Drugs. https://doi.org/10.1007/s10637-021-01164-9
Source records
- crossref · retrieved 2026-09-27T14:15:57.662Z